Top 5 Papers
#1
Source: JAMA Surgery | Authors: Berlth F, Gisbertz SS, Tagkalos E, et al. (Grimminger PP, senior author) | Published: September 30, 2026
Score: 12/20 — Base 7 (JAMA Surgery) + 3 (Phase III RCT) + 2 (practice-defining surgical comparison) = 12. The impact bonus is deliberately held at +2 rather than the full +3 for new standard of care: the primary endpoint is a surrogate — number of resected lymph nodes — and 1-year survival did not differ between arms, so the trial establishes technical superiority, not yet an outcome benefit.
RAMIE (robot-assisted minimally invasive esophagectomy) was compared head-to-head against conventional minimally invasive esophagectomy in a phase 3 randomized trial across four high-volume tertiary centres in Mainz, Amsterdam, Zurich and Cologne. Of 218 patients randomized between January 2021 and March 2025, 202 underwent transthoracic esophagectomy for cT1-4a, cN0-3, cM0 adenocarcinoma of the esophagus or esophagogastric junction (101 per arm; mean age 64.8 years, 89.6% male). The primary endpoint was met: median resected lymph nodes 36 with RAMIE versus 32 with MIE (P = .005). Luminal R0 resection was 99.0% versus 97.0%, postoperative complication rates were similar, 90-day mortality was 1.0% versus 3.0% (P = .62), and there was no difference in survival at 1 year. This digest covered a RAMIE-versus-MIE meta-analysis in May whose GRADE certainty was rated very low because the pooled data were predominantly non-randomised — and notably, the randomised trial reproduces the nodal yield but not the morbidity advantage that meta-analysis reported.
Post angle: The randomised answer to a question that had only low-certainty observational data: robotic esophagectomy delivers a more radical lymphadenectomy at equal surgical safety — but the morbidity advantage claimed by meta-analysis did not replicate, and survival is unchanged at 1 year. #GIOnc #EsophagealCancer #Surgery #RAMIE
#2
Source: Nature Medicine | Authors: Yap TA, Fontana E, Cook N, Fakih M, et al. (Postel-Vinay S, senior author) | Published: September 29, 2026
Score: 12/20 — Base 9 (Nature Medicine) + 1 (Phase I / first-in-human, per the established Phase 1 = +1 rule) + 1 (biomarker-guided precision — synthetic lethality restricted to an MSI/dMMR-selected population) + 1 (colleague engagement: one GI oncology KOL posted it within 48h) = 12. Included under the Tier-1 Journal Safety-Net Rule as a pan-tumor topic with direct GI relevance: MSI/dMMR is the defining biomarker of Lynch-associated colorectal cancer and a recurring one in sporadic colorectal and gastric cancer.
Werner syndrome helicase (WRN) has been a known synthetic-lethal dependency of microsatellite-unstable cancers for years without a drug to exploit it; this first-in-human phase 1 is the first clinical test of one. Part 1 escalated RO7589831 (VVD-133214), described by the authors as a first-in-class covalent WRN inhibitor, in 88 patients with MSI and/or mismatch-repair-deficient advanced solid tumours, dosed once daily, twice daily (150–1,000 mg) or three times daily (200–600 mg). Tolerability was the headline: a single dose-limiting toxicity (grade 2 nausea at 600 mg TID), the maximum tolerated dose never reached, mostly grade 1–2 toxicity, and only 3.4% (3/88) discontinuing for adverse events, with no grade 5 events. Among MSI efficacy-evaluable patients, disease control was 74.2% (49/66) but confirmed RECIST v1.1 partial responses numbered only seven (ORR 10.6%, 7/66), with median DOR 10.2+ months, median PFS 6.7 months (95% CI 4.1–8.5) and median OS 17.6 months. Direct target engagement in tumour tissue could not be demonstrated, though ctDNA and FDG-PET analyses supported biological activity; 150 mg and 600 mg BID were taken forward as recommended phase 2 doses.
Post angle: A synthetic-lethal target that has sat undruggable since the WRN dependency was mapped finally has a clinical agent — and the phase 1 reads exactly like a phase 1 should: outstanding tolerability, 74.2% disease control, and a sobering 10.6% response rate. The mechanism is the news, not the efficacy. #GIOnc #CRC #MSI #PrecisionMedicine
#3
Source: Nature Medicine | Authors: VIRAGE phase 2b investigators (Theriva Biologics; NCT05673811) | Published: September 30, 2026
Score: 13/20 — Base 9 (Nature Medicine) + 2 (randomised phase 2b) + 2 (survival benefit — PFS significant in both ITT and FAS, and duration of response HR 0.22) = 13. Placed third despite carrying the highest score in this edition: this digest already covered the VIRAGE AACR 2026 topline as a Top paper on April 18, 2026, and the standing rule is that an already-covered topline's full publication is reported but never re-led. The score is recorded at its true value so the ranking is not silently distorted.
VCN-01 (zabilugene almadenorepvec) is an oncolytic adenovirus engineered to express soluble hyaluronidase, degrading the hyaluronic-acid-dense stroma that makes pancreatic tumours impenetrable to chemotherapy. This randomized phase 2b gave two intravenous doses of VCN-01 with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone as first-line therapy in metastatic pancreatic ductal adenocarcinoma. In the intent-to-treat population (VCN-01 + GnP n=53; GnP n=48), median OS was 10.6 versus 8.6 months — HR 0.69 (95% CI 0.42–1.12), P = 0.196, not significant — while PFS was 5.6 versus 4.6 months, HR 0.63 (95% CI 0.4–1.00), P = 0.046. In the full analysis set (n=48 per group) median OS was 10.8 versus 8.6 months, HR 0.57 (95% CI 0.34–0.96), P = 0.055, and PFS 7.0 versus 4.6 months, HR 0.55 (95% CI 0.34–0.88), P = 0.011; the authors report the primary OS endpoint as met in the FAS population. The most striking signal is durability rather than depth: duration of response was 11.2 versus 5.4 months, HR 0.22 (95% CI 0.08–0.63), P = 0.004, and landmark survival was 35.5% versus 12.8% at 15 months and 31.1% versus 8.5% at 18 months — yet there were no significant differences in overall response rate, disease control rate or CA19-9. Patients given two doses 14 weeks apart benefited most, with sustained circulating viral genomes indicating preserved second-dose bioactivity despite persistent neutralizing antibodies. Serious VCN-01-related events occurred in 22.6%, chiefly pyrexia, flu-like symptoms, transaminase elevation and thrombocytopenia, and were milder after the second dose; two fatal events occurred, one per arm, neither treatment-related. This digest covered the AACR 2026 topline on April 18, 2026 — this is the full peer-reviewed dataset behind it.
Post angle: The interesting thing is not that tumours shrank more — they did not, with ORR, DCR and CA19-9 all flat. It is that responses lasted more than twice as long (DOR 11.2 vs 5.4 months, HR 0.22), which is exactly what you would predict if opening the stroma keeps chemotherapy reaching the tumour. The caveat is equally clear: ITT overall survival was negative at P=0.196, and the win sits in a full analysis set that is five patients smaller in the experimental arm. #PDAC #PancreaticCancer #GIOnc #OncolyticVirus
Additional Papers of Interest
-
Gastroenterology / American Journal of Gastroenterology — review and consensus statement from the US Multi-Society Task Force on Colorectal Cancer, published simultaneously in both journals. SPS is identified as the most common polyposis syndrome and one that frequently goes unrecognized; diagnosis stays on WHO clinical criteria (size, cumulative lifetime number and location of serrated polyps), with meticulous inspection, clearing of the colon and frequent surveillance colonoscopy to reduce incident CRC, and surgery reserved for cancer or an endoscopically unmanageable polyp burden. There is no common germline pathogenic variant, so germline testing is indicated only when a known hereditary syndrome is independently suspected; first-degree relatives should undergo colonoscopic screening.
-
Nature Communications — first stage of an open-label single-arm phase 2 of motixafortide (CXCR4 inhibitor) plus cemiplimab and gemcitabine/nab-paclitaxel in 11 treatment-naive metastatic PDAC patients. ORR 64% partial response with 55% confirmed; median PFS 9.7 months, median OS 10.1 months, duration of response 8.2 months, disease control 91%; one pathological complete response after pancreatoduodenectomy and hepatectomy, disease-free at 18 months. Single-nucleus RNA-sequencing showed depletion of EMT states and enrichment of CXCL12+ cancer-associated fibroblasts in responders. With n=11 and no comparator, the OS does not separate from gemcitabine/nab-paclitaxel alone; a randomised phase 2 is ongoing.
-
International Journal of Cancer — prospective single-arm phase II, 25 patients with potentially resectable cholangiocarcinoma given six cycles of neoadjuvant mFOLFOXIRI. ORR 44.0% (11 partial responses); 20 patients (80.0%) became resectable and 16 (64.0%) underwent curative-intent resection with an R0 rate of 75.0%; major pathological response in 2 of 16 resected (12.5%). Median RFS 18.93 months, median OS 26.70 months; grade 3–4 neutropenia 36.0% with no treatment-related deaths. Single-arm with no comparator, so the resection-conversion rate carries the signal, not the survival figures.
-
Journal of Hepato-Biliary-Pancreatic Sciences — PRISMA systematic review and meta-analysis of 8 studies and 5,094 patients (transplant 2,289; resection 2,805). Liver transplantation showed significantly higher overall survival at 3, 5 and 10 years with 1-year OS similar, and superior disease-free survival at every timepoint with progressively larger benefits over time. No randomised trials exist on the question — every included study was observational with substantial baseline differences, and the authors explicitly warn this limits causal interpretation. The abstract reports direction and significance but not the magnitude of the pooled estimates.
-
Diseases of the Colon and Rectum — National Cancer Database analysis of 90,724 resected low-risk stage II colon adenocarcinomas (2010–22); 7.9% still received adjuvant chemotherapy and use fell ~30% over the period, driven by fewer multiagent regimens. Age under 50 (OR 2.25, p<0.001), KRAS mutation (OR 1.39, p=0.005) and nonacademic centres predicted treatment; MSI-high tumours predicted against it (OR 0.59, p=0.001). The unadjusted survival advantage disappeared after adjustment, HR 0.998 (95% CI 0.709–1.404).
-
Journal of Gastrointestinal Surgery — propensity-score-matched cohort of 233 locally advanced gastric cancers treated with neoadjuvant immunochemotherapy, 188 after 1:1 matching. Adding postoperative immunotherapy to adjuvant chemotherapy produced no gain in 3-year disease-free survival (75.5% vs 77.6%, P=0.534) or 3-year overall survival (86.1% vs 88.2%, P=0.593), while immune-related adverse events rose from 27.66% to 43.62% (P=0.021). Retrospective; awaits randomised confirmation.
-
JHEP Reports — two cohorts (184 and 259 patients without cirrhosis, against 1,173 and 841 with cirrhosis) from Vienna, Sorbonne Paris and the AB-Real/DT-Real immunotherapy databases. CTP class was independently associated with overall survival in non-cirrhotic HCC in both cohorts, adjusted HR 3.04 (95% CI 1.70–5.45) and 3.24 (95% CI 1.73–6.08), both p<0.001, independent of BCLC stage; ALBI grade performed similarly, with time-dependent AUROCs comparable to the cirrhotic population.
-
Gut — comparative study of GLP-1 receptor agonists versus DPP-4 inhibitors in patients with type 2 diabetes following curative resection of HCC, addressing which glucose-lowering class to favour in a population at high risk of recurrence. No abstract is available in PubMed at the time of this digest, so no endpoint figures are quoted here.
Back to all digests